Boardroom Alpha
Boardroom Alpha
NTRB · Amended Annual Report (Form 10-K/A) · Filed May 18, 2026

Nutriband Inc — Amended Annual Report (Form 10-K/A)

Form
10-K/A
Filed
May 18, 2026
Period
Jan 31, 2026
Ticker
NTRB
Accession
0001213900-26-058507
About Nutriband Inc
Market cap
$43M
1Y TSR
−52.4%
3Y TSR
+11.2%
Board grade
C
Sector
Healthcare
CEO
Gareth Sheridan
Last annual meeting: Jan 24, 2026 · View full Nutriband Inc profile →

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

AMENDMENT NO. 1

 

TO

 

FORM 10-K

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended January 31, 2026

 

or

 

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to __________

 

Commission file number 000-40854

  

NUTRIBAND INC.

(Exact name of registrant as specified in its charter)

 

Nevada   81-1118176
(State or other jurisdiction of
Incorporation or organization)
  (I.R.S. Employer
Identification No.)

 

121 South Orange Ave., Suite 1500, Orlando, FL   32801
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (407) 377-6695

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock    NTRB    The Nasdaq Stock Market LLC
Warrants   NTRBW   The Nasdaq Stock Market LLC

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐  No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.

 

Note - Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Exchange Act from their obligations under those Sections.

 

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒  No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒  No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐  No ☒

 

* * *

 

 

 

 

 

 

EXPLANATORY NOTE

 

NUTRIBAND EXECUTIVE CLAWBACK POLICY

 

The Company is filing this Amendment No. 1 to its Form 10-K for the fiscal year ended January 31, 2026 (the “2026 10-K”) to file the Policy Relating to Recovery of Erroneously Awarded Compensation (the ‘Clawback Policy’) as Exhibit 97.1 to the 2026 10-K, which was omitted from the original filing. The Company adopted the Clawback Policy on January 24, 2026, in compliance with applicable NASDAQ listing standards and SEC Rule 10D-1, but failed to include the policy as an exhibit in the original filing of the 2026 10-K. This Amendment to Item 15 of the Company’s 2026 10-K does not reflect events occurring after the filing of the original  2026 10-K or modify or update the disclosure contained therein in any way other than to reflect the adoption of the Clawback Policy.

 

1

 

 

PART IV

 

ITEM 15 Exhibits.

 

Exhibit    
Number   Description
1.1   [Reserved]
3.1A   Articles of Incorporation.(1)
3.1B   Amendment to Articles of Incorporation, filed May 12, 2016.(1)
3.1   Certificate of Amendment filed January 21, 2020. (Filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed January 27, 2020).
3.1C   Certificate of Change, filed with the Nevada Secretary of State on August 4, 2022.(13)
3.1D   Amendment to Articles of Incorporation, filed with the Nevada Secretary of State on July 16, 2025.(21)
3.2   By-laws(1)
3.2B   Amended and Restated By-Laws adopted January 21, 2022.(12)
4.3   Securities purchase agreement dated October 29, 2019 among the Company, Jefferson Street Capital LLC and Platinum Point Capital LLC(6)
4.4   Form of convertible 6% promissory note issued pursuant to Exhibit 4.3 (6)
4.10   Form of Common Stock Purchase Warrant issued to Platinum Point Capital LLC and Jefferson Street Capital LLC(6)
4.14†   2021 Employee Stock Option Plan.(11)
4.15†   Form of Stock Option Grant Notice.(11)
4.16   Form of Common Stock Purchase Warrant issued in the Company’s initial public offering in 2021(9)
4.17   Form of Warrant issued to the Representative.(14)
4.18†   2024 Amended and Restated Stock Option Plan, adopted March 20, 2024.(15)
4.19   Form of Common Stock Purchase Warrant issued in 2024 Equity Financi1ng (18)
5.1   [Reserved]
10.1   Share exchange agreement dated January 15, 2016 by and among the Company, Nutriband Limited, an Ireland corporation, and Gareth Sheridan and/or his nominee(1)
10.4   Acquisition agreement dated April 5, 2018 between the Company and 4P Therapeutics LLC.(3)
10.5†   Form of agreement with independent directors.(4)
10.6   Exclusive master distribution agreement dated April 13, 2018 between the Company and EMI-Korea (Best Choice), Inc.(4)
10.15†   Employment Agreement, dated April 23, 2019, between Gareth Sheridan and the Company.(5)
10.16†   Employment Agreement, dated April 23, 2019, between Serguei Melnik and the Company.(5)
10.17†   Employment Agreement, dated February 19, 2019, between Jeffrey Patrick and the Company.(5)
10.18†   Employment Agreement, dated January 1, 2018, between Sean Gallagher and the Company.(5)
10.19   Purchase Agreement, dated August 31, 2020, by and among the Company and Pocono Coated Products, LLC.(7)

 

2

 

 

10.20   Security Agreement, between the Company and Pocono Coated Products, LLC.(7)
10.21   Promissory Note Issued by the Company on August 31, 2020 to Pocono Coated Products, LLC.(7)
10.22   License Agreement, dated December 9, 2020, between the Company and Rambam Med-Tech Ltd.(8)
10.23   Distribution Agreement, dated March 26, 2021, between the Company and BPM Inno Ltd.(8)
10.24   Stock Purchase Agreement, dated December 7, 2020, between the Company and BPM Inno Ltd.(8)
10.25   Amendment No. 1 to Purchase Agreement, dated August 31, 2020, by and among the Company and Pocono Coated Products, LLC(8a)
10.26   Services Agreement dated October 4, 2021, between Active Intelligence, LLC and Diomics Corporation.(10)
10.27†   Employment Agreement effective February 1, 2022, between the Company and Gareth Sheridan.(12)
10.28†   Employment Agreement effective February 1, 2022, between the Company and Serguei Melnik.(12)
10.29†   Employment Agreement effective February 1, 2022, between the Company and Gerald Goodman.(12)
10.30   Creditline Promissory Note, dated July 13, 2023. (16)
10.31   Conversion Agreement, dated December 19, 2023.(17)
10.32   Form of Subscription Agreement for April 19, 2024 Equity Financing (19)
10.33   Form of Note Conversion Agreement dated May 13, 202420
10.35   Commercial Development and Clinical Supply Agreement (“Agreement”), made on January 4, 2023, between Kindeva Drug Delivery, L.P. and 4P Therapeutics, LLC., filed as Exhibit 10.35 to the Company’s Annual Report on Form 10-K, filed with the SEC on April 28, 2025.
10.36   Amendment No. 1, dated as of February 4, 2025, to the Commercial Development and Clinical Supply Agreement, by and between Kindeva Drug Delivery L.P. and 4P Therapeutics, LLC., filed as Exhibit 10.36 to the Company’s Annual Report on Form 10-K, filed with the SEC on April 28, 2025.
21.1   List of Subsidiaries of Nutriband Inc.(14)
23.1   [Reserved]
31.1   Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act.*
31.2   Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act.*
32.1   Certification of the Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley.*
32.2   Certification of the Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley.*
97.1   Executive Compensation Clawback Policy†*
101.INS   Inline XBRL Instance Document.*
101.SCH   Inline XBRL Taxonomy Extension Schema Document.*
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.*
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.*
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.*
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.*
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
107   Filing Fee Table

 

* Filed herewith.
   
Executive compensation plan or arrangement.
   
(1) Filed as exhibit to the Company’s registration statement on Form 10, which was filed with the Commission on June 2, 2016, and incorporated herein by reference.

 

(2) Filed as an exhibit to the Company’s report on Form 8-K, which was filed with the Commission on January 27, 2020 and incorporated herein by reference.
   
(3) Filed as an exhibit to the Company’s report on Form 8-K, which was filed with the Commission on April 10, 2018 and incorporated herein by reference.
   
(4) Filed as an exhibit to the Company’s annual report on Form 10-K for the year ended January 3, 2019 which was filed with the Commission on April 19, 2019, and incorporated herein by reference.

 

3

 

 

(5) Filed as an exhibit to the Company’s Registration Statement on Form S-1/A, which was filed with the Commission on May 19, 2020, and incorporated herein by reference.

 

(6) Filed as an exhibit to the Company’s report on Form 8-K, which was filed with the Commission on November 4, 2019, and incorporated herein by reference.

 

(7) Filed as an exhibit to the Company’s report on Form 8-K, which was filed with the Commission on September 4, 2020, and incorporated herein by reference.
   
(8) Filed as exhibits to the Company’s report on Form 8-K, which was filed with the Commission on March 11, 2021, and incorporated herein by reference.
   
(8a) Filed as an exhibit to the Company’s report on Form 8-K, which was filed with the Commission on September 1, 2021, and incorporated herein by reference.
   
(9) Filed as Exhibit 4.12 to Amendment 2 to the Company’s Registration Statement on Form S-1, which was filed with the Commission on October 1, 2021.
   
(10) Filed as an exhibit to the Company’s Current Report on Form 8-K, which was filed with the Securities and Exchange Commission on October 12, 2021, and incorporated herein by reference.
   
(11) Filed as an exhibit to the Company’s Registration Statement on Form S-8, which was filed with the Commission on November 5, 2021, and incorporated herein by reference.
   
(12) Filed as an exhibit to the Company’s Current Report on Form 8-K, which was filed with the Commission on January 27, 2022, and incorporated herein by reference.
   
(13) Filed as Exhibit 3.1C to the Company’s Current Report on Form 8-K, which was filed with the Commission on August 10, 2022, and incorporated herein by reference.
   
(14) Filed as an exhibit to the Company’s Registration Statement on Form S-1, which was filed with the Commission on June 26, 2023, and incorporated herein by reference
   
(15) Filed as Exhibit 4.16 to the Company’s Amendment No. to its Current Report on Form 8-K, which was filed with the Commission on March 28, 2024 and incorporated herein by reference.
   
(16) Filed as Exhibit 10.30 to the Company’s Current Report on Form 8-K, which was filed with the Commission on July 14, 2023.
   
(17) Filed as Exhibit No. 10.31 to the Company’s Current Report on Form 8-K, which was filed with the Commission on December 29, 2023.
   
(18) Filed as Exhibit No.  4.19 to the Company’s Current Report on Form 8-K, which was filed with the Commission on April 23, 2024.
   
(19) Filed as Exhibit No. 10.32 to the Company’s Current Report on Form 8-K, which was filed with the Commission on April 23, 2024.
   
(20) Filed as Exhibit No. 10.33 to the Company’s Current Report on Form 8-K, which was filed with the Commission on May 21, 2024.
   
(21) Filed as Exhibit 3.1D to the Company’s Current Report on form 8-K, filed with the Commission on July 14, 2025.

 

(b) Financial Statement Schedules

 

All schedules have been omitted because either they are not required, are not applicable or the information is otherwise set forth in the financial statements and related notes thereto.

 

4

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Amendment to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: May 18, 2026

 

  NUTRIBAND INC.
   
  By: /s/ Gareth Sheridan 
    Gareth Sheridan
    Chief Executive Officer
     
  By: /s/ Gerald Goodman 
    Gerald Goodman
    Chief Financial Officer
(Principal Financial and Accounting Officer)

 

Signature   Title   Date
         
/s/ Gareth Sheridan   Chief Executive Officer and Director   May 18, 2026
Gareth Sheridan        
         
/s/ Serguei Melnik   Director   May 18, 2026
Serguei Melnik        
         
  Director  
Sergei Glinka        
         
/s/ Radu Bujoreanu   Director   May 18, 2026 
Radu Bujoreanu        
         
/s/ Mark Hamilton    Director   May 18, 2026 
Mark Hamilton        
         
/s/ Stefani Mancas   Director   May 18, 2026
Stefani Mancas        
         
/s/ Irina Gram   Director   May 18, 2026
Irina Gram        
         
  Director    
Viorica Carlig        
         
  Director    
Alessandro Pudu        

 

5

 

From this filing to the analytics

The analytics layer on top of every filing.

Boardroom Alpha scores every director and executive, tracks pay-for-performance, surfaces risk-factor changes, and forecasts every annual meeting — on every U.S. public company.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Nutriband Inc (NTRB)

Reference

Frequently asked questions

When did Nutriband Inc file this 10-K/A?
Nutriband Inc (NTRB) filed this Amended Annual Report (Form 10-K/A) with the SEC on May 18, 2026. The accession number assigned by EDGAR is 0001213900-26-058507.
What does a 10-K/A disclose?
Form 10-K is the SEC's annual report. Public companies use it to disclose audited financial statements, risk factors, management's discussion and analysis (MD&A), executive compensation, board-of-director information, and a comprehensive description of the business. It is the most-detailed disclosure document a U.S. issuer files each year.
Where can I find the risk factors and MD&A in this 10-K?
Risk factors appear in Item 1A and Management's Discussion and Analysis in Item 7 of the filing text above. The financial statements (Item 8) include the income statement, balance sheet, cash-flow statement, and notes.
Where can I find Nutriband Inc's prior annual reports on EDGAR?
The SEC EDGAR browser lists every 10-K/A Nutriband Inc has filed under CIK 1676047, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer